Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy. [Review]
Citation: Heart Failure Clinics. 13(2):297-309, 2017 AprPMID: 28279416Institution: MedStar Heart & Vascular Institute | MedStar Washington Hospital CenterDepartment: Medicine/CardiologyForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Heart Failure/ci [Chemically Induced] | *Neoplasms/dt [Drug Therapy] | *Protein Kinase Inhibitors/ae [Adverse Effects] | Heart Failure/me [Metabolism] | Heart Failure/pp [Physiopathology] | Heart Ventricles/pp [Physiopathology] | Humans | Neoplasms/me [Metabolism] | Neoplasms/pp [Physiopathology] | Protein Kinase Inhibitors/pd [Pharmacology] | Receptor, Epidermal Growth Factor/ai [Antagonists & Inhibitors] | Signal Transduction/de [Drug Effects] | Ventricular Function, Left/de [Drug Effects]Year: 2017ISSN:- 1551-7136
| Item type | Current library | Collection | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
| Journal Article | MedStar Authors Catalog | Article | 28279416 | Available | 28279416 |
Cancer therapy targeting the epidermal growth factor receptor (EGFR)/erythroblastic leukemia viral oncogene B (ErbB)/human EGFR receptor (HER) family of tyrosine kinases has been successfully used in treatment of several malignancies. The ErbB pathways play a role in the maintenance of cardiac homeostasis. This article summarizes current knowledge about EGFR/ErbB/HER receptor-targeted cancer therapeutics focusing on their cardiotoxicity profiles, molecular mechanisms, and implications in clinical cardio-oncology. The article discusses challenges in predicting, monitoring, and treating cardiac dysfunction and heart failure associated with ErbB-targeted cancer therapeutics and highlights opportunities for researchers and clinical investigators.
Copyright (c) 2016 Elsevier Inc. All rights reserved.
English